Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has established long-term stable partnerships with globally recognized suppliers and downstream customers, which is expected to further strengthen its competitive advantage [7][8] - The decline in the selling prices of the company's main products has led to a year-on-year decrease in profits [5] - The company has slightly revised down its profit forecast for 2025-2027, predicting net profits of 1.03 billion, 1.12 billion, and 1.26 billion respectively, with corresponding PE ratios of 31.0, 28.7, and 25.4 times [9] Financial Performance - In the first half of 2025, the company achieved operating revenue of 218 million, a year-on-year increase of 0.02%, and a net profit attributable to shareholders of 34 million, a year-on-year decrease of 21.72% [4] - The revenue from the piperazine series products in the first half of 2025 was 177 million, a year-on-year decrease of 7.56%, while the revenue from the amide series products increased by 82.73% to 25 million [5] - The financial expense ratio increased due to reduced interest income from structured deposits [6] Profit Forecast - The company forecasts operating revenues of 457 million, 502 million, and 579 million for 2025, 2026, and 2027 respectively, with growth rates of -2.4%, 9.7%, and 15.4% [11] - The net profit attributable to shareholders is expected to grow at rates of 27.4%, 8.1%, and 12.7% for the same years [11]
兴欣新材（001358）：优质客户资源助力成长，竞争优势进一步巩固